Home › Mantelcellymfoom › Texas › Houston
Mantelcellymfoom klinische studies in Houston, TX
15 studies voor Mantelcellymfoom zoeken deelnemers op locaties in en rond Houston (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RekruterenFase 1/2
- Research Site, Houston
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RekruterenFase 3
- Md Anderson Cancer Center, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruterenFase 1/2
- Md Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruterenFase 1
- MD Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RekruterenFase 1/2
- Research Site, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruterenFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RekruterenFase 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RekruterenFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RekruterenFase 1
- MD Anderson Cancer Center, Houston
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RekruterenFase 2
- M D Anderson Cancer Center, Houston
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
RekruterenFase 2Gezonde vrijwilligers welkom
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RekruterenFase 1
- MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RekruterenFase 1
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruterenObservatieonderzoek
- Massive Bio SYNERGY-AI site, Houston
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
RekruterenFase 2
- M D Anderson Cancer Center, Houston
Mantelcellymfoom studies in andere steden
- Baldwin Park, CA15 studies
- Durham, NC13 studies
- New York City, NY12 studies
- Seattle, WA12 studies
- Milwaukee, WI12 studies
- Boston, MA11 studies
- Columbus, OH11 studies
- Nashville, TN11 studies
- Chicago, IL10 studies
- Portland, OR9 studies
- Rochester, MN9 studies
- St. Louis, MO8 studies
Andere studies in Houston
- Niet-kleincellige longkanker145 studies
- Borstkanker126 studies
- Kanker (alle vormen)121 studies
- Metastatische kanker104 studies
- Colorectale kanker102 studies
- Eierstokkanker89 studies
- Acute myeloïde leukemie85 studies
- Longkanker78 studies
- Prostaatkanker76 studies
- Endometriumkanker68 studies
- Aldermeesklierkanker61 studies
- Melanoom59 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.